BTIG Maintains Buy on Castle Biosciences, Lowers Price Target to $30
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Mark Massaro maintains a Buy rating on Castle Biosciences (NASDAQ:CSTL) but lowers the price target from $38 to $30.
June 15, 2023 | 4:24 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Castle Biosciences' price target has been lowered from $38 to $30 by BTIG analyst Mark Massaro, who maintains a Buy rating.
The news of BTIG analyst Mark Massaro maintaining a Buy rating on Castle Biosciences (NASDAQ:CSTL) is positive for the stock. However, the lowering of the price target from $38 to $30 may create some uncertainty among investors, leading to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100